Huaheng Biotech Passes HKEX Hearing, Ranks No.1 Globally in L-Alanine Market Share
Claire Weston
Huaheng Biotech (688639.SH) has cleared its HKEX main board listing hearing, bringing the world's top L-alanine producer one step closer to Hong Kong funding — but revenue growth paired with shrinking profits makes profitability the key question for investors.
Why is this company listing in Hong Kong?
HKEX disclosed on June 22 that Huaheng Biotech passed its main board hearing. Huatai International is the sole sponsor.
The company is already A-share listed (688639.SH). This Hong Kong move is a dual listing — the same company tapping a second exchange for capital.
This means → Huaheng wants access to offshore funding to bankroll its next phase of expansion.
What technology put it at global No. 1?
Huaheng is the world's first company to industrialize anaerobic fermentation for L-alanine and L-valine. In plain terms = it uses microbes in oxygen-free tanks to "brew" amino acids — greener and cheaper than traditional chemical synthesis.
According to Frost & Sullivan, Huaheng ranked No. 1 globally in both L-alanine and L-valine market share by 2024 revenue.
This reflects a core moat built not on scale but on process-pioneering advantage — it had the biotech route running while competitors were still on chemistry.
How wide is the product portfolio?
The company runs two technology platforms: fermentation + enzymatic catalysis, producing three product families: amino acids, vitamins, and other bio-based products.
End-use spans animal nutrition, personal care, food & beverage, materials, and plant nutrition.
As of end-2025, Huaheng served over 815 clients across 89 countries, covering major markets in Asia, Europe, and the Americas.
Revenue is growing — so why are profits falling?
Revenue for 2023–2025 came in at roughly RMB 1.94 bn, 2.18 bn, and 2.86 bn — up nearly 50% over three years.
Net profit over the same period: roughly RMB 447 m, 185 m, and 124 m — a steep, continuous slide. By 2025, profit was less than 30% of the 2023 level.
This means → the company is in a "selling more, earning less" phase, possibly driven by new product lines not yet profitable, intensifying price competition, or front-loaded expansion costs.
In plain terms = scale is growing, but margins are not following — Hong Kong investors will be watching one question above all: when does operating leverage actually kick in?
Content is for reference only, not financial advice.